Irritable Bowel Syndrome (IBS)

1. Clinical Overview

Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits (diarrhoea, constipation, or both) in the absence of identifiable organic pathology. [1,2] It represents the most common disorder of gut-brain interaction (previously termed "functional gastrointestinal disorder"), affecting quality of life comparably to chronic conditions such as diabetes and inflammatory bowel disease. [3]

IBS is not a diagnosis of exclusion, but rather a positive clinical diagnosis based on symptom-based criteria (Rome IV) combined with judicious use of investigations to exclude alarm features. [4] The pathophysiology is multifactorial, involving visceral hypersensitivity, altered gut motility, gut microbiota dysbiosis, low-grade inflammation, and psychological factors mediated through the gut-brain axis. [5,6]

The condition does not progress to inflammatory bowel disease or colorectal cancer, and does not increase mortality. However, it confers substantial morbidity through reduced quality of life, work absenteeism, and healthcare utilization. [7] Management is individualized, combining dietary modification, pharmacotherapy targeted to predominant symptoms, and psychological interventions.

Clinical Pearls

Nocturnal Diarrhoea - The "Sleeping Bowel" Rule: The normal gastrointestinal tract exhibits reduced motility during sleep. Symptoms that wake a patient from sleep to defecate strongly suggest organic pathology (inflammatory bowel disease, bile acid malabsorption, microscopic colitis) rather than IBS. [8] This is a critical discriminating feature in clinical assessment.

Rectal Bleeding is NEVER IBS: While patients with established IBS may develop coincidental haemorrhoids or other sources of bleeding, new rectal bleeding must always be investigated to exclude colorectal cancer, inflammatory bowel disease, or other structural pathology. Never attribute bleeding to IBS alone. [9]

The "Diagnosis of Exclusion" Trap: Traditional teaching portrayed IBS as a diagnosis made after exhaustive negative investigations. Modern practice emphasizes making a positive diagnosis using validated criteria (Rome IV) early in the clinical course, which improves patient satisfaction, reduces healthcare costs, and prevents unnecessary invasive investigations. [4,10] The key is to recognize when alarm features mandate investigation versus when clinical diagnosis is appropriate.

Post-Defecation Pain Relief: A hallmark feature distinguishing IBS from organic disease is improvement in abdominal pain following defecation. [11] This symptom should be actively enquired about during history taking.

---

2. Epidemiology

Prevalence and Demographics

IBS is a highly prevalent condition affecting 10-15% of the global population, with significant geographic variation. [1,12] Prevalence estimates range from 5% in some Asian populations to over 20% in Western countries, likely reflecting differences in diagnostic criteria, dietary factors, and healthcare-seeking behavior. [13]

Gender and Age Distribution

• Female Predominance: IBS is 2-3 times more common in women than men. [14] This gender disparity is most pronounced for IBS with constipation (IBS-C) and may relate to hormonal influences, visceral sensitivity differences, and psychosocial factors.
• Age at Diagnosis: Most patients develop symptoms before age 50. [15] New onset symptoms after age 60 warrant thorough investigation for colorectal cancer and should trigger urgent referral via 2-week-wait pathways in the UK.
• Paediatric IBS: Affects 10-15% of adolescents, with similar symptom profiles to adults. [17]

Risk Factors

1. Post-Infectious IBS (PI-IBS)

   • Develops in 10-15% of patients following acute gastroenteritis. [18]
   • Risk factors: Severity of acute illness, prolonged duration, female gender, psychological distress at time of infection.
   • Common precipitants: Campylobacter jejuni, Salmonella, Shigella, Escherichia coli.
   • Pathophysiology involves persistent low-grade inflammation, altered gut microbiota, and epithelial barrier dysfunction.

2. Psychological Comorbidity

   • Strong bidirectional association with anxiety disorders (prevalence 40-60%) and depression (30-40%). [19]
   • History of physical or sexual abuse associated with increased IBS prevalence and severity. [20]
   • Stress exacerbates symptoms through corticotropin-releasing factor (CRF) pathways affecting gut motility and visceral sensitivity.

3. Dietary Factors

   • High intake of fermentable carbohydrates (FODMAPs) correlates with symptom severity. [21]
   • Food intolerances (lactose, fructose, gluten sensitivity) may overlap with or mimic IBS.

4. Genetic Predisposition

   • Twin studies suggest heritability of 22-33%. [22]
   • Genetic polymorphisms identified in serotonin transporter genes, immune function, and bile acid metabolism.

5. Antibiotic Exposure

   • Disruption of gut microbiota (dysbiosis) associated with IBS development. [23]
   • May lead to small intestinal bacterial overgrowth (SIBO) in susceptible individuals.

Socioeconomic Impact

• Work Productivity: IBS patients miss 3 times more work days than controls. [24]
• Quality of Life: Comparable impairment to chronic conditions like diabetes mellitus and inflammatory bowel disease. [3]
• Healthcare Utilization: Accounts for 25-50% of gastroenterology consultations in primary and secondary care. [16]

---

3. Aetiology and Pathophysiology

IBS is a multifactorial disorder involving complex interactions between biological, psychological, and social factors. The pathophysiology involves visceral hypersensitivity, altered gastrointestinal motility, gut microbiota dysbiosis, immune activation, and central nervous system dysregulation through the gut-brain axis. [5,6]

Mechanisms of Disease

1. Visceral Hypersensitivity

Central to IBS pathophysiology is enhanced perception of normal intestinal stimuli. [25]

• Peripheral Sensitization: Increased density and excitability of visceral afferent neurons in the gut wall respond to luminal distension, chemicals, and inflammation.
• Central Sensitization: Altered processing in the dorsal horn and brain leads to amplification of pain signals. Functional brain imaging shows altered activation in the anterior cingulate cortex, insula, and prefrontal cortex in response to rectal distension. [26]
• Clinical Manifestation: Normal physiological events (gas, peristalsis, low-volume distension) are perceived as painful.

2. Gastrointestinal Motility Disturbances

• IBS with Diarrhoea (IBS-D): Accelerated colonic transit, reduced segmental contractions. [27]
• IBS with Constipation (IBS-C): Delayed colonic transit, increased segmental contractions preventing propulsion. [28]
• Postprandial Symptoms: Exaggerated gastrocolic reflex leads to pain and urgency after meals.
• Serotonin Dysregulation: 95% of body's serotonin (5-HT) is in enterochromaffin cells. Altered 5-HT3 and 5-HT4 receptor signaling affects motility and visceral sensation. [29]

3. Gut-Brain Axis Dysfunction

Bidirectional communication between the enteric nervous system and central nervous system is disrupted. [30]

• Bottom-Up Signaling: Visceral afferents transmit exaggerated signals to CNS.
• Top-Down Modulation: Psychological stress, anxiety, and depression amplify pain perception through descending pathways.
• Neurotransmitters: Serotonin, corticotropin-releasing factor (CRF), substance P, and brain-derived neurotrophic factor (BDNF) are implicated.
• Hypothalamic-Pituitary-Adrenal (HPA) Axis: Dysregulated stress response with elevated cortisol and CRF perpetuates symptoms.

4. Gut Microbiota Dysbiosis

Alterations in intestinal microbiota composition and diversity are consistently observed. [31]

• Reduced Diversity: Decreased abundance of beneficial Bifidobacterium and Lactobacillus species.
• Increased Proteobacteria: Associated with gas production and inflammation.
• Small Intestinal Bacterial Overgrowth (SIBO): Detected in 30-40% of IBS patients, particularly IBS-D, though diagnostic criteria and relevance remain debated. [32]
• Metabolic Products: Increased production of short-chain fatty acids, methane, and hydrogen contributes to bloating and altered motility.

5. Low-Grade Inflammation and Immune Activation

Evidence of subtle immune activation despite normal endoscopic appearance. [33]

• Mucosal Immune Cells: Increased mast cells, T lymphocytes, and enterochromaffin cells in intestinal mucosa.
• Cytokine Profile: Elevated pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in subsets of patients.
• Epithelial Barrier Dysfunction: Increased intestinal permeability ("leaky gut") allows luminal antigens to activate immune responses. [34]
• Post-Infectious IBS: Persistent immune activation following resolved gastroenteritis.

6. Dietary Triggers and Food Hypersensitivity

• FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols): Poorly absorbed short-chain carbohydrates are rapidly fermented, producing gas and osmotic load. [21]
• Bile Acid Malabsorption (BAM): Present in 25-30% of IBS-D patients, causing secretory diarrhoea through colonic bile acid stimulation. [35]
• Non-Coeliac Gluten Sensitivity: Subset of IBS patients report improvement on gluten-free diet independent of coeliac disease. [36]

Exam Detail: Detailed Molecular Mechanisms for Postgraduate Examinations:

Serotonin Signaling:

• 5-HT3 receptors: Located on vagal afferents; mediate nausea and visceral pain. 5-HT3 antagonists (alosetron, ondansetron) reduce diarrhea and pain in IBS-D.
• 5-HT4 receptors: Prokinetic effects; agonists (prucalopride, tegaserod) accelerate transit in IBS-C.
• SERT (Serotonin Transporter): Polymorphisms affect serotonin reuptake, influencing bowel function and mood.

Corticotropin-Releasing Factor (CRF) Pathway:

• CRF released from hypothalamus during stress activates CRF-1 and CRF-2 receptors in gut.
• Increases colonic motility, visceral sensitivity, and intestinal permeability.
• CRF antagonists show promise in preclinical models.

TLR-Mediated Immune Activation:

• Toll-like receptors (TLR2, TLR4) on enterocytes recognize bacterial products.
• Activation triggers NF-κB signaling, releasing pro-inflammatory cytokines.
• Persistent low-grade activation contributes to visceral hypersensitivity.

Intestinal Barrier Function:

• Tight junctions (occludin, claudins, ZO-1) maintain barrier integrity.
• Increased permeability allows bacterial translocation and antigen presentation.
• Mast cell tryptase and histamine further disrupt barrier and activate nociceptors.

---

4. Clinical Presentation

Diagnostic Criteria: Rome IV

The Rome IV criteria (2016) provide the current diagnostic framework for IBS. [37] Diagnosis requires:

Recurrent abdominal pain, on average at least 1 day per week in the last 3 months, associated with 2 or more of the following:

1. Related to defecation (may increase or decrease pain)
2. Associated with a change in frequency of stool
3. Associated with a change in form (appearance) of stool

Additional Requirements:

• Criteria fulfilled for the last 3 months
• Symptom onset at least 6 months prior to diagnosis
• No evidence of structural or biochemical abnormalities to explain symptoms

Cardinal Symptoms

Abdominal Pain

• Character: Cramping, colicky, or constant ache. Variable location, often lower abdomen.
• Relationship to Defecation: Typically improves after bowel movement (distinguishes from other causes). [11]
• Triggers: Meals (postprandial pain common), stress, menstruation in women.
• Absence of Nocturnal Symptoms: Pain that wakes patient from sleep suggests organic disease. [8]

Altered Bowel Habit

• Diarrhoea: Loose or watery stools (Bristol types 6-7), often with urgency. Frequency typically 3-5 bowel movements per day.
• Constipation: Hard or lumpy stools (Bristol types 1-2), straining, feeling of incomplete evacuation.
• Alternating Pattern: Fluctuation between diarrhoea and constipation over days to weeks.

Associated Features

Extraintestinal Manifestations

IBS frequently overlaps with other functional disorders and conditions:

• Fibromyalgia: 32% of IBS patients; shared central sensitization mechanisms. [39]
• Chronic Pelvic Pain: 35-50% of women with IBS report dysmenorrhea, dyspareunia. [40]
• Interstitial Cystitis/Bladder Pain Syndrome: 30% prevalence in IBS cohorts.
• Temporomandibular Joint Disorder: Increased prevalence.
• Migraine Headaches: 23-35% prevalence versus 15% in general population. [41]
• Psychological Comorbidity: Anxiety (40-60%), depression (30-40%), somatization. [19]

IBS Subtypes (Based on Predominant Stool Pattern)

Classification uses the Bristol Stool Form Scale on days with abnormal bowel habits. [42]

Clinical Note: Subtypes can change over time; reassessment of predominant pattern guides therapy adjustments.

Red Flag Features (Alarm Symptoms)

The presence of any red flag mandates investigation to exclude organic disease:

---

5. Differential Diagnosis

IBS is a clinical diagnosis, but several important conditions must be considered and excluded where appropriate.

Gastrointestinal Causes

Gynecological Causes (Women)

Other Functional GI Disorders

• Functional Dyspepsia: Epigastric pain/discomfort, early satiety, postprandial fullness. Often overlaps with IBS (40%).
• Chronic Constipation (Functional): Constipation without pain (does not meet IBS criteria).
• Functional Diarrhoea: Chronic diarrhea without pain.

Systemic Conditions

• Hyperthyroidism: Diarrhea, weight loss despite appetite, tremor, tachycardia. Check TSH.
• Diabetes Mellitus: Diabetic autonomic neuropathy causing gastroparesis or diarrhea.
• Hypercalcaemia: Constipation, abdominal pain, polyuria. Check corrected calcium.

---

6. Investigations

The goal of investigations is to exclude alarm features and specific differential diagnoses while avoiding unnecessary invasive tests in patients meeting Rome IV criteria without red flags. [4,47]

Initial Assessment (All Patients)

The "IBS Screen" (Based on NICE/BSG Guidelines):

Additional First-Line Tests (Based on Clinical Context):

• CA-125 (women > 50 with bloating): Ovarian cancer screening. [46]
• Faecal Immunochemical Test (FIT): Age > 50, family history CRC, rectal bleeding. [9]
• Erythrocyte Sedimentation Rate (ESR): Alternative inflammatory marker if CRP unavailable.

Second-Line Investigations (Based on Subtype and Symptoms)

For IBS-D (Diarrhoea-Predominant)

For IBS-C (Constipation-Predominant)

For Persistent/Atypical Symptoms

Investigations NOT Routinely Recommended

Unless specific indications present:

• Routine Colonoscopy in patients less than 50 without red flags (low yield, invasive, costly). [47]
• Abdominal Ultrasound/CT without alarm features.
• Extensive Allergy Testing (poor evidence base).
• Stool Cultures in chronic diarrhea without travel/acute onset.

Exam Detail: Investigation Pearls for Examinations:

Faecal Calprotectin:

• Sensitivity: 93% for IBD; Specificity: 94% at threshold > 50 μg/g. [43]
• False positives: NSAIDs, PPIs, infection, colorectal cancer.
• Serial measurements improve accuracy if initial borderline (50-150 μg/g).

SeHCAT Scan (Bile Acid Retention):

• Nuclear medicine test measuring 75Se-homocholic acid taurine retention at 7 days.
• less than 10%: Severe BAM; 10-15%: Moderate; > 15%: Normal.
• Empirical trial of bile acid sequestrants (cholestyramine, colesevelam) is alternative if scan unavailable.

SIBO Breath Testing:

• Controversial: poor standardization, high false positive/negative rates.
• Glucose test (more specific for small bowel overgrowth) vs. lactulose (more sensitive but detects colonic fermentation).
• Rise in H2 ≥20 ppm or CH4 ≥10 ppm within 90 minutes considered positive.

Anorectal Manometry + Balloon Expulsion Test:

• Identifies dyssynergic defecation (paradoxical anal sphincter contraction).
• Present in 40% of severe constipation; managed with pelvic floor biofeedback therapy.

---

7. Management

IBS management is individualized, symptom-directed, and combines patient education, dietary modification, pharmacotherapy, and psychological interventions. No single treatment is universally effective; therapeutic trials and adjustments are routine. [48]

Management Principles

1. Establish Positive Diagnosis: Use Rome IV criteria; avoid conveying "diagnosis of exclusion." [4]
2. Patient Education and Reassurance: Explain benign prognosis, lack of cancer/IBD risk, multifactorial mechanisms.
3. Therapeutic Relationship: Validate symptoms, acknowledge impact on quality of life.
4. Identify Predominant Symptom: Pain, diarrhea, constipation, or bloating directs therapy.
5. Stepwise Approach: Lifestyle → Diet → Pharmacotherapy → Psychological interventions.
6. Address Comorbidity: Treat anxiety/depression, fibromyalgia, other functional disorders.

---

Step 1: Patient Education and Lifestyle Modification

Explanation of IBS Mechanism

Patients benefit from understanding:

• Visceral Hypersensitivity: Gut nerves are "tuned up," making normal sensations painful.
• Gut-Brain Axis: Stress and emotions influence gut function bidirectionally.
• Benign Nature: No progression to cancer or IBD; normal life expectancy. [7]
• Chronic, Fluctuating Course: Symptoms wax and wane; management aims for control, not cure.

Lifestyle Recommendations

• Regular Meal Pattern: Three meals daily; avoid prolonged fasting or binge eating.
• Adequate Hydration: 1.5-2 L fluids daily, especially for IBS-C.
• Physical Activity: Moderate exercise (30 min, 5×/week) improves symptoms and quality of life. [49]
• Stress Management: Sleep hygiene, relaxation techniques, mindfulness.
• Reduce Triggers:
  • Caffeine (stimulates colonic motility)
  • Alcohol (irritant, increases motility)
  • Carbonated beverages (bloating)
  • Spicy foods (if triggers identified)

---

Step 2: Dietary Interventions

First-Line Dietary Advice (General)

• Fiber Modification:
  • "IBS-D: Reduce insoluble fiber (bran, raw vegetables)."
  • "IBS-C: Increase soluble fiber (oats, ispaghula husk/psyllium). [50]"
  • Avoid wheat bran (may worsen bloating).
• Limit Resistant Starch: Found in processed foods, reheated potatoes/rice.
• Reduce Fat Intake: High-fat meals slow gastric emptying, increase colonic motility.

Low FODMAP Diet (Second-Line, Dietitian-Supervised)

FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols) are poorly absorbed short-chain carbohydrates that undergo rapid fermentation, producing gas and osmotic diarrhea. [21]

Efficacy: 50-70% of IBS patients experience symptom improvement. [21,51]

High FODMAP Foods to Restrict (Elimination Phase, 4-6 weeks):

Low FODMAP Alternatives:

• Grains: Gluten-free bread, rice, quinoa, oats
• Vegetables: Carrots, cucumber, lettuce, tomatoes, zucchini
• Fruits: Banana, blueberries, grapes, oranges, strawberries
• Proteins: Meat, fish, eggs, tofu
• Dairy: Lactose-free milk, hard cheeses (cheddar, parmesan)

Reintroduction Phase (Essential):

• Systematically reintroduce FODMAP groups one at a time to identify specific triggers.
• Prevents unnecessary dietary restriction and nutritional deficiencies.
• Requires dietitian guidance.

Limitations:

• Adherence challenging; restrictive.
• Risk of nutritional inadequacy (calcium, fiber).
• Social impact on eating out.

Probiotics

• Evidence: Modest benefit for global IBS symptoms and bloating; strain-specific effects. [52]
• Recommended Trial: Single-strain or multi-strain probiotic for 4-12 weeks.
• Examples: Bifidobacterium infantis 35624, Lactobacillus plantarum 299v, VSL#3 (multi-strain).
• No universal recommendation on specific strain or dose.

Gluten-Free Diet

• May benefit subset with non-coeliac gluten sensitivity (after coeliac disease excluded). [36]
• Trial for 6-8 weeks if symptoms suggest gluten link.
• Not recommended routinely for all IBS patients.

---

Step 3: Pharmacological Management (Symptom-Targeted)

For Abdominal Pain and Spasm

1. Antispasmodics (First-Line)

Peppermint Oil: Enteric-coated formulation releases in small bowel/colon, avoiding esophageal reflux. Effective for pain and bloating. [54]

2. Low-Dose Tricyclic Antidepressants (Second-Line)

Mechanism: Neuromodulation of visceral pain pathways, independent of antidepressant effect. Analgesic at doses far below antidepressant range (5-30 mg vs. 75-150 mg). [55]

Use: IBS with moderate-to-severe pain refractory to antispasmodics. Particularly useful for IBS-D (slows transit).

Side Effects: Dry mouth, constipation, sedation (use evening dosing). Warn about anticholinergic effects.

3. Selective Serotonin Reuptake Inhibitors (SSRIs) (Alternative)

Mechanism: Accelerate colonic transit (prokinetic effect); treat comorbid anxiety/depression. [56]

Preferred for: IBS-C, patients with prominent anxiety.

Caution: May worsen diarrhea in IBS-D.

---

For IBS-D (Diarrhoea-Predominant)

1. Loperamide (First-Line)

• Dose: 2-4 mg PRN (up to 16 mg/day).
• Mechanism: Opioid μ-receptor agonist; slows transit, increases anal sphincter tone.
• Evidence: Reduces stool frequency and urgency; minimal effect on pain or bloating. [57]
• Use: Take 30-60 minutes before meals or events (anticipatory dosing).

2. Bile Acid Sequestrants

Use: IBS-D with chronic watery diarrhea, especially post-cholecystectomy or ileal disease/resection.

SeHCAT scan positive (less than 15%) or empirical trial for 4 weeks.

Side Effects: Bloating, constipation, fat-soluble vitamin deficiency (long-term use).

3. Rifaximin (Non-Absorbed Antibiotic)

• Dose: 550 mg TDS for 14 days.
• Evidence: Modestly effective for IBS-D (targeting SIBO/dysbiosis). FDA-approved in USA; unlicensed in UK (used off-label/privately). [58]
• Repeat Courses: May be required; safe with minimal resistance.

4. Eluxadoline (Peripheral μ-Opioid Receptor Agonist)

• Dose: 75-100 mg BD.
• Mechanism: Mixed μ/δ-opioid agonist, κ-antagonist; reduces secretion and transit.
• Use: Severe IBS-D refractory to other treatments. FDA-approved; not routinely available in UK.
• Contraindication: History of pancreatitis, cholecystectomy (risk of sphincter of Oddi spasm).

5. 5-HT3 Receptor Antagonists

---

For IBS-C (Constipation-Predominant)

1. Osmotic Laxatives (First-Line)

Avoid: Stimulant laxatives (senna, bisacodyl) long-term; may worsen pain.

2. Soluble Fiber (Ispaghula Husk/Psyllium)

• Dose: 3.5 g BD with water.
• Mechanism: Bulking agent; increases stool water content.
• Evidence: Improves stool frequency and consistency in IBS-C. [50]

3. Linaclotide (Guanylate Cyclase-C Agonist)

• Dose: 290 μg daily (on empty stomach).
• Mechanism: Increases intestinal fluid secretion and transit; reduces visceral hypersensitivity. [61]
• Evidence: Effective for IBS-C pain, bloating, and bowel function (NNT 6).
• Side Effect: Diarrhea (10-20%; dose-dependent).
• Availability: Licensed in UK and USA for IBS-C.

4. Lubiprostone (Chloride Channel Activator)

• Dose: 8 μg BD.
• Mechanism: Activates ClC-2 channels; increases intestinal fluid secretion.
• Evidence: Effective for IBS-C. FDA-approved (USA); not licensed in UK. [62]

5. Prucalopride (5-HT4 Agonist)

• Dose: 1-2 mg daily.
• Mechanism: Prokinetic; accelerates colonic transit.
• Use: Chronic constipation (licensed); used off-label for severe IBS-C. [63]

---

For Bloating

• First-Line: Dietary modification (low FODMAP), probiotics.
• Pharmacological: Rifaximin (if SIBO suspected), simethicone (limited evidence).
• Avoid: Excessive fiber (worsens bloating).

---

Step 4: Psychological and Behavioral Therapies

Psychological interventions are effective for IBS, particularly in patients with comorbid anxiety/depression or stress-triggered symptoms. [64]

Cognitive Behavioral Therapy (CBT)

• Mechanism: Addresses maladaptive thought patterns, coping strategies, and illness behaviors.
• Delivery: Face-to-face, group, or internet-based CBT.
• Evidence: NNT 3-4 for symptom improvement. [64]
• Duration: 6-12 sessions.

Gut-Directed Hypnotherapy

• Mechanism: Hypnotic suggestions targeting gut function and pain perception.
• Evidence: Highly effective (NNT 2-4); sustained benefit up to 5 years. [65]
• Availability: Specialist centers; trained therapists required.
• Ideal for: Moderate-to-severe IBS, high anxiety, visceral hypersensitivity.

Mindfulness-Based Stress Reduction (MBSR)

• Mechanism: Meditation and mindfulness techniques reduce stress and visceral sensitivity.
• Evidence: Modest benefit for IBS symptoms and quality of life. [66]

Psychotherapy and Counseling

• For patients with trauma history, significant psychiatric comorbidity, or somatization.

---

Step 5: Specialist and Multidisciplinary Management

Indications for Gastroenterology Referral:

• Red flag symptoms requiring endoscopy.
• Refractory symptoms despite first- and second-line therapies.
• Diagnostic uncertainty.
• Suspected overlap with other functional GI disorders (dyspepsia, chronic pelvic pain).

Multidisciplinary Team:

• Gastroenterologist: Diagnosis, exclude organic disease, prescribe specialist therapies.
• Dietitian: Low FODMAP diet supervision, nutritional assessment.
• Psychologist/Psychotherapist: CBT, hypnotherapy, stress management.
• Pain Specialist: Chronic pain management (if severe, refractory pain).

---

Management Algorithm Summary

        POSITIVE DIAGNOSIS (Rome IV)
     + Normal Screening Investigations
                    ↓
        PATIENT EDUCATION & REASSURANCE
    - Explain visceral hypersensitivity
    - Gut-brain axis
    - Benign prognosis (no cancer/IBD risk)
                    ↓
          LIFESTYLE MODIFICATION
    - Regular meals
    - Reduce caffeine, alcohol, spicy food
    - Exercise, stress management
                    ↓
          DIETARY INTERVENTIONS
    - General fiber advice (soluble for IBS-C)
    - Low FODMAP diet (dietitian-led)
    - Probiotics (4-12 week trial)
                    ↓
       PHARMACOTHERAPY (Symptom-Targeted)
        ┌──────────┼──────────┬──────────┐
      PAIN     DIARRHOEA   CONSTIPATION  BLOATING
        ↓           ↓           ↓           ↓
  Antispasmodic Loperamide  Macrogol   Low FODMAP
   (Mebeverine)              (PEG)      Probiotics
   Peppermint Oil  Bile Acid  Linaclotide Rifaximin
                 Sequestrants
   TCA (Amitript.) Rifaximin  Prucalopride
   (10-30 mg)
   SSRI (IBS-C)
                    ↓
       PSYCHOLOGICAL THERAPIES
    - CBT
    - Gut-directed hypnotherapy
    - Mindfulness-based stress reduction
                    ↓
         SPECIALIST REFERRAL
    - Refractory symptoms
    - Diagnostic uncertainty
    - Multidisciplinary input

---

Exam Detail: Pharmacotherapy Pearls for Examinations:

Low-Dose TCAs (Amitriptyline 10-30 mg):

• Mechanism: Inhibits noradrenaline and serotonin reuptake in descending pain pathways; anticholinergic effects slow transit.
• Onset: 2-4 weeks for pain benefit.
• NNT: 4 for global symptom improvement. [55]
• Preferred in: IBS-D or IBS-M with pain.
• Caution: Elderly (falls risk, cognitive effects), cardiac disease (QT prolongation), glaucoma, urinary retention.

SSRIs (Citalopram 10-20 mg):

• Mechanism: Prokinetic (5-HT4 stimulation); anxiolytic.
• Preferred in: IBS-C with comorbid anxiety/depression. [56]
• Onset: 4-6 weeks.
• Side Effects: Nausea (transient), diarrhea (may worsen IBS-D).

Linaclotide (290 μg for IBS-C):

• Mechanism: GC-C agonist → ↑ cGMP → ↑ CFTR chloride secretion → ↑ intestinal fluid + transit; also reduces visceral afferent signaling (analgesia). [61]
• Dual Effect: Improves pain AND bowel function (unique among laxatives).
• NNT: 6 for adequate relief.
• Side Effect: Diarrhea (dose-dependent; often resolves with continued use).
• Administration: Empty stomach (30 min before breakfast); swallow whole.

Rifaximin (550 mg TDS × 14 days):

• Mechanism: Non-absorbed antibiotic; targets gut microbiota (SIBO), reduces bacterial fermentation and endotoxin-mediated inflammation. [58]
• Evidence: Modest benefit for IBS-D bloating and global symptoms; repeat courses safe.
• NNT: 10-11 for adequate relief.
• Off-label in UK; FDA-approved (USA).

---

8. Complications

IBS is a functional disorder without structural pathology and does not cause life-threatening complications. However, it has significant psychosocial and quality of life impacts. [7]

Quality of Life Impairment

• Work Absenteeism: IBS patients miss 3 times more work days than healthy controls. [24]
• Social Functioning: Avoidance of social events, travel, dining out due to fear of symptoms (especially diarrhea/urgency).
• Sexual Dysfunction: Dyspareunia in women with pelvic pain overlap; reduced libido.
• Healthcare Utilization: Frequent consultations, investigations, polypharmacy.

Psychological Comorbidity

• Anxiety Disorders: Prevalence 40-60%. [19]
• Depression: Prevalence 30-40%; bidirectional relationship (depression worsens IBS; IBS worsens depression).
• Somatization: Tendency to experience and communicate psychological distress as physical symptoms.
• Health Anxiety: Fear of serious undiagnosed disease despite reassurance.

Nutritional and Eating Concerns

• Avoidant/Restrictive Food Intake Disorder (ARFID): Extreme dietary restriction due to fear of symptom triggers.
• Malnutrition Risk: Particularly with overly restrictive low FODMAP diets without reintroduction phase.
• Eating Disorders: Overlap with anorexia nervosa, bulimia in subset of patients.

Medication Overuse

• Laxative Dependency: Chronic stimulant laxative use may worsen colonic function.
• Opioid Use: Risk of opioid-induced constipation, dependency; opioids should be avoided in IBS.

Unnecessary Investigations and Procedures

• Repeat Colonoscopies: In absence of new red flags.
• Cholecystectomy: IBS symptoms mistaken for biliary colic; surgery does not resolve symptoms.
• Appendicectomy: Higher rate of appendicectomy in IBS patients (functional pain misattributed). [67]

---

9. Prognosis and Outcomes

Natural History

• Chronic, Fluctuating Course: Symptoms wax and wane over months to years. [7]
• Spontaneous Resolution: 10-20% experience sustained remission over 5-10 years, particularly if symptom onset in adolescence.
• Symptom Severity: Majority report persistent symptoms but with variable severity.
• Subtype Stability: 30-50% change IBS subtype (IBS-C ↔ IBS-D ↔ IBS-M) over time.

Long-Term Outcomes

Prognostic Factors

Poor Prognosis (Persistent Severe Symptoms):

• Severe baseline symptoms.
• Comorbid anxiety, depression, somatization. [19]
• History of childhood trauma or abuse. [20]
• Longer symptom duration before diagnosis.
• Poor therapeutic alliance with healthcare providers.
• Maladaptive coping strategies (catastrophizing, hypervigilance).

Good Prognosis:

• Younger age at onset.
• Absence of psychiatric comorbidity.
• Good patient-physician relationship.
• Early diagnosis and reassurance.
• Effective symptom management.

Response to Treatment

• Dietary Therapy: 50-70% respond to low FODMAP diet. [21,51]
• Pharmacotherapy: 40-60% benefit from targeted therapies (antispasmodics, TCAs, secretagogues). [53,55,61]
• Psychological Therapy: 60-80% improve with CBT or hypnotherapy. [64,65]
• Placebo Response: High (30-40%) in IBS trials, reflecting gut-brain interaction and expectation effects.

---

10. Prevention and Screening

Primary Prevention

No specific strategies prevent IBS development, but modifiable risk factors may be addressed:

• Healthy Diet: Balanced diet, adequate fiber, hydration.
• Stress Management: Mindfulness, regular exercise, adequate sleep.
• Judicious Antibiotic Use: Minimize disruption to gut microbiota. [23]

Post-Infectious IBS Prevention

• Early Intervention: Probiotics during/after gastroenteritis may reduce PI-IBS risk (limited evidence).
• Psychological Support: Addressing anxiety during acute illness may reduce risk. [18]

Screening

No Screening Programs for IBS (not a precancerous condition).

Screening for Differential Diagnoses:

• Colorectal Cancer: FIT screening programs (age ≥50) may detect cancer in patients misattributed to IBS.
• Coeliac Disease: Serological screening mandatory in IBS diagnostic workup. [44]
• Ovarian Cancer: CA-125 and pelvic ultrasound in women > 50 with new-onset bloating. [46]

---

11. Key Guidelines

---

12. Evidence and Landmark Studies

Landmark Evidence

1. Low FODMAP Diet (Halmos et al., 2014)

• RCT demonstrating 70% of IBS patients improve on low FODMAP diet versus 30% on control diet. [51]
• Established FODMAP restriction as evidence-based dietary intervention.
• Monash University developed comprehensive FODMAP food database and app.

2. Gut-Directed Hypnotherapy (Whorwell et al., 1984, 2002)

• Long-term efficacy (> 5 years) of gut-directed hypnotherapy for IBS symptoms. [65]
• NNT 2-4; comparable efficacy to pharmacotherapy with sustained benefit.

3. Rifaximin for IBS-D (Pimentel et al., TARGET 1 and 2, 2011)

• Phase 3 RCTs showing rifaximin 550 mg TDS × 14 days effective for global IBS-D symptoms. [58]
• Led to FDA approval for IBS-D (USA).

4. Linaclotide for IBS-C (Rao et al., 2012)

• RCTs demonstrating dual benefit for abdominal pain and constipation in IBS-C. [61]
• First therapy with analgesic and prokinetic properties.

5. Post-Infectious IBS (Spiller et al., 2000)

• Prospective cohort study establishing 10-15% incidence of PI-IBS after Campylobacter gastroenteritis. [18]
• Identified persistent mucosal inflammation and increased enterochromaffin cells.

6. Tricyclic Antidepressants Meta-Analysis (Ford et al., 2014)

• Meta-analysis of 12 RCTs; TCAs effective for global IBS symptoms (NNT 4). [55]
• Effect independent of depression treatment; low doses effective.

---

13. Examination Focus

Common Exam Questions

1. "What are the Rome IV criteria for IBS?"

Answer: Recurrent abdominal pain at least 1 day per week in the last 3 months (with symptom onset ≥6 months prior), associated with 2 or more of:

• Related to defecation
• Change in stool frequency
• Change in stool form

2. "What investigations would you perform in a patient with suspected IBS?"

Answer: Initial screen to exclude differential diagnoses:

• FBC (anaemia)
• CRP/ESR (inflammation)
• Coeliac serology (anti-TTG IgA + total IgA) - mandatory
• Faecal calprotectin (exclude IBD)
• TSH (thyroid dysfunction)
• CA-125 (if female > 50 with bloating, to exclude ovarian cancer)

Further investigation only if red flags present or abnormal initial tests.

3. "A patient with IBS-D has failed loperamide. What would you try next?"

Answer: Consider:

• Bile acid sequestrants (cholestyramine 4 g OD-TDS) - empirical trial or SeHCAT scan if available, especially post-cholecystectomy
• Low-dose TCA (amitriptyline 10-30 mg ON) for pain and to slow transit
• Rifaximin (550 mg TDS × 14 days) if SIBO suspected or off-label trial
• Dietary modification: Low FODMAP diet with dietitian

4. "What is the role of colonoscopy in IBS diagnosis?"

Answer: Colonoscopy is not routinely required for IBS diagnosis in patients less than 50 without red flags who meet Rome IV criteria. [47] Indications for colonoscopy:

• Age > 50 with new symptoms
• Red flags: rectal bleeding, weight loss, anaemia, raised inflammatory markers, FIT positive
• Family history of colorectal cancer or IBD
• Raised faecal calprotectin (> 150 μg/g)

5. "Describe the pathophysiology of IBS."

Answer: Multifactorial disorder involving:

• Visceral hypersensitivity: Central and peripheral sensitization leading to enhanced pain perception from normal gut stimuli
• Altered motility: Accelerated transit (IBS-D) or delayed transit (IBS-C)
• Gut-brain axis dysfunction: Bidirectional signaling between ENS and CNS; stress exacerbates symptoms
• Gut microbiota dysbiosis: Altered composition, SIBO in subset
• Low-grade inflammation: Increased mast cells, cytokines, mucosal permeability (especially post-infectious IBS)
• Psychological factors: Anxiety, depression, trauma amplify perception and distress

---

Viva Points

Viva Point: Opening Statement: "Irritable Bowel Syndrome is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits—diarrhoea, constipation, or both—in the absence of organic pathology. It affects 10-15% of the population, with a 2:1 female predominance, and is diagnosed using Rome IV criteria."

Key Facts to Mention:

• Positive Diagnosis: Not a diagnosis of exclusion; Rome IV criteria allow confident diagnosis without extensive investigation.
• Red Flags: Rectal bleeding, nocturnal diarrhoea, weight loss, age > 50 mandate investigation for colorectal cancer, IBD.
• Pathophysiology: Visceral hypersensitivity, gut-brain axis dysfunction, dysbiosis.
• Subtypes: IBS-C (constipation), IBS-D (diarrhoea), IBS-M (mixed) guide therapy.
• Management: Stepwise—education, lifestyle, diet (low FODMAP), symptom-targeted pharmacotherapy (antispasmodics, TCAs, loperamide, linaclotide), psychological therapies (CBT, hypnotherapy).
• Prognosis: Benign; no increased cancer risk or mortality; chronic, fluctuating course.

Common Follow-Up Questions:

"What is the gut-brain axis?"

• Bidirectional communication between enteric nervous system and central nervous system.
• Mediated by vagus nerve, neurotransmitters (serotonin, CRF), gut microbiota metabolites.
• Stress/anxiety increase gut motility, visceral sensitivity, and symptom severity.
• Explains overlap of IBS with anxiety, depression, and efficacy of psychological therapies.

"Why do we use low-dose amitriptyline in IBS?"

• Pain neuromodulation (not antidepressant effect).
• Inhibits noradrenaline/serotonin reuptake in descending pain pathways, reducing visceral hypersensitivity.
• Anticholinergic effects slow colonic transit (beneficial in IBS-D).
• Dose: 5-30 mg (sub-antidepressant).
• NNT 4 for global symptom improvement. [55]

"What is the evidence for low FODMAP diet?"

• FODMAPs are poorly absorbed short-chain carbohydrates causing gas and osmotic diarrhea.
• RCT (Halmos et al., 2014): 70% response rate vs. 30% on control diet. [51]
• Requires dietitian supervision and reintroduction phase to avoid unnecessary restriction.

"What is bile acid malabsorption and how do you diagnose it?"

• Excess bile acids in colon stimulate secretion and motility → watery diarrhea.
• Affects 25-30% of IBS-D patients. [35]
• Diagnosis: SeHCAT scan (less than 10-15% retention at 7 days) or empirical trial of bile acid sequestrant (cholestyramine, colesevelam).
• Often post-cholecystectomy, ileal disease/resection, or idiopathic.

---

Common Mistakes

❌ Attributing rectal bleeding to IBS without investigation (colonoscopy mandatory).

❌ Failing to exclude coeliac disease (anti-TTG serology is mandatory in IBS workup).

❌ Overlooking nocturnal diarrhoea as a red flag for organic disease (IBD, microscopic colitis, bile acid malabsorption).

❌ Performing colonoscopy in young patients (less than 50) without red flags (unnecessary, costly, invasive; positive diagnosis with Rome IV criteria is sufficient). [47]

❌ Prescribing opioids for IBS pain (worsen constipation, risk of dependency; use antispasmodics, TCAs instead).

❌ Using high-dose TCAs (75-150 mg) when low doses (5-30 mg) are effective and better tolerated for pain neuromodulation.

❌ Recommending low FODMAP diet without dietitian supervision or reintroduction phase (risk of malnutrition, unnecessary restriction).

❌ Failing to address psychological comorbidity (anxiety, depression worsen symptoms; treat with SSRIs, CBT, or hypnotherapy).

---

Model Answers

Q: A 28-year-old woman presents with 9 months of crampy lower abdominal pain, bloating, and alternating diarrhoea and constipation. Pain improves after defecation. No rectal bleeding, weight loss, or nocturnal symptoms. Describe your approach.

A: "This presentation is suggestive of Irritable Bowel Syndrome (IBS), specifically IBS-M (mixed subtype) based on alternating bowel habits. My approach would be:

1. History:

• Confirm Rome IV criteria: abdominal pain ≥1 day/week for 3 months, associated with defecation and change in stool frequency/form.
• Exclude red flags: No rectal bleeding, weight loss, nocturnal diarrhoea, or family history of colorectal/ovarian cancer mentioned.
• Assess triggers: Diet (FODMAPs, lactose), stress, menstrual cycle.
• Psychological comorbidity: Anxiety, depression.

2. Examination:

• Abdominal examination (exclude masses, organomegaly, tenderness suggestive of other pathology).
• Digital rectal examination (if indicated by symptoms).

3. Investigations (IBS Screen):

• FBC (anaemia), CRP (inflammation), coeliac serology (anti-TTG IgA + total IgA - mandatory), faecal calprotectin (exclude IBD), TSH (thyroid dysfunction).
• No colonoscopy needed (age less than 50, no red flags).

4. Management:

• Education: Explain IBS as functional disorder, benign prognosis, no cancer risk.
• Lifestyle: Regular meals, reduce caffeine/alcohol, exercise, stress management.
• Diet: Trial low FODMAP diet (dietitian-supervised), probiotics (4-12 weeks).
• Pharmacotherapy (symptom-targeted):
  • "Pain/bloating: Antispasmodic (mebeverine 135 mg TDS) or peppermint oil."
  • "Diarrhoea: Loperamide 2-4 mg PRN."
  • "Constipation: Macrogol (polyethylene glycol) 1-2 sachets daily."
  • "If inadequate response: Low-dose TCA (amitriptyline 10 mg ON, increase to 20-30 mg)."
• Psychological therapy: Consider CBT or hypnotherapy if anxiety present or refractory symptoms.

5. Follow-Up:

• Review response at 4-6 weeks.
• Adjust therapy based on predominant symptom.
• Reassess for new red flags."

---

Q: What is post-infectious IBS and what is its pathophysiology?

A: "Post-infectious IBS (PI-IBS) develops in approximately 10-15% of patients following an episode of acute gastroenteritis, commonly caused by Campylobacter jejuni, Salmonella, Shigella, or E. coli. [18]

Risk Factors for PI-IBS:

• Severity and duration of acute infection
• Female gender
• Psychological distress at time of infection
• Younger age

Pathophysiology:

• Persistent Low-Grade Inflammation: Increased mucosal immune cells (T lymphocytes, mast cells, enterochromaffin cells) despite resolution of infection. [33]
• Epithelial Barrier Dysfunction: Increased intestinal permeability allows bacterial antigens to activate immune responses.
• Dysbiosis: Altered gut microbiota composition persists post-infection.
• Visceral Hypersensitivity: Inflammatory mediators (cytokines, histamine, serotonin) sensitize visceral afferents, leading to enhanced pain perception.

Clinical Implication: PI-IBS validates the organic basis of IBS symptoms and supports immune-modulating therapies (e.g., probiotics, rifaximin)."

---

14. Patient and Layperson Explanation

What is IBS?

Irritable Bowel Syndrome (IBS) is a common condition where your gut becomes oversensitive. The nerves in your bowel wall are more reactive than usual, so normal things like gas bubbles, food moving through, or the bowel contracting—which most people don't notice—are felt by your brain as pain or cramping.

Is it all in my head?

No. The pain and discomfort are real. However, your gut and brain are closely connected through nerves (called the gut-brain axis). Stress, anxiety, and emotions can make the pain signals stronger, and gut symptoms can affect your mood. It's a two-way street. Think of it like turning up the volume on a radio—the sound (gut activity) is the same, but your brain perceives it as louder.

Is it something I ate?

Often, yes. Certain foods ferment in your gut more than others, producing gas that stretches the sensitive bowel wall and causes pain and bloating. Common culprits include:

• Onions, garlic
• Wheat-based foods (bread, pasta)
• Dairy (milk, soft cheese, ice cream)
• Beans and lentils
• Stone fruits (peaches, plums, cherries)
• Artificial sweeteners

A specialized diet called the low FODMAP diet can help identify which foods trigger your symptoms. A dietitian can guide you through this.

Will it turn into cancer or something serious?

No. IBS is a functional problem—it affects how your gut works, not its structure. It does not turn into bowel cancer, inflammatory bowel disease (like Crohn's or ulcerative colitis), or any other serious condition. People with IBS have the same life expectancy as everyone else. However, it's important to investigate any new symptoms like bleeding, weight loss, or symptoms starting after age 50, as these are not typical of IBS.

How do I treat it?

Treatment is tailored to your symptoms and involves several steps:

1. Understanding and Reassurance: Knowing what IBS is and that it's not dangerous helps reduce anxiety.

2. Lifestyle Changes:

   • Eat regular meals (don't skip meals or overeat).
   • Drink plenty of water.
   • Exercise regularly.
   • Manage stress (yoga, mindfulness, good sleep).
   • Cut down on caffeine, alcohol, and very spicy foods.

3. Diet:

   • Try a low FODMAP diet with a dietitian's help to find trigger foods.
   • Consider probiotics (good bacteria supplements) for 4-12 weeks.

4. Medications (depending on your main symptom):

   • For pain and cramping: Antispasmodic tablets like mebeverine (Colofac) or hyoscine (Buscopan), or peppermint oil capsules.
   • For diarrhoea: Loperamide (Imodium) to slow down the bowel.
   • For constipation: Laxatives like Movicol (polyethylene glycol) or medications like linaclotide that help the bowel move.
   • For ongoing pain: Low-dose amitriptyline (a nerve pain medicine) can "turn down the volume" on the pain signals.

5. Talking Therapies:

   • Cognitive Behavioral Therapy (CBT): Helps change unhelpful thoughts and behaviors around gut symptoms.
   • Hypnotherapy: Specialized gut-focused hypnotherapy is very effective for many people.

Can it be cured?

IBS is a chronic, long-term condition that comes and goes. There's no permanent cure, but most people can control their symptoms well with the right combination of diet, lifestyle, and treatment. Many people find their symptoms improve over time, especially with effective management.

When should I see a doctor urgently?

See a doctor straight away if you develop any of these warning signs, as they are not typical of IBS:

• Blood in your poo (rectal bleeding)
• Waking up at night with diarrhoea
• Unintentional weight loss
• Severe or worsening pain
• A lump in your tummy
• Family history of bowel or ovarian cancer
• Age over 50 with new symptoms

---

15. References

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721. doi:10.1016/j.cgh.2012.02.029

2. Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393-1407. doi:10.1053/j.gastro.2016.02.031

3. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119(3):654-660. doi:10.1053/gast.2000.16484

4. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. doi:10.2147/CLEP.S40245

5. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367(17):1626-1635. doi:10.1056/NEJMra1207068

6. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest. 2015;125(3):926-938. doi:10.1172/JCI76304

7. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500-1511. doi:10.1053/gast.2002.32978

8. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75. doi:10.1053/j.gastro.2013.09.046

9. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NG12). Updated 2021. https://www.nice.org.uk/guidance/ng12

10. Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017;376(26):2566-2578. doi:10.1056/NEJMra1607547

11. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-1491. doi:10.1053/j.gastro.2005.11.061

12. Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66(6):1075-1082. doi:10.1136/gutjnl-2015-311240

13. Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed. J Gastroenterol Hepatol. 2009;24(10):1601-1607. doi:10.1111/j.1440-1746.2009.05984.x

14. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991-1000. doi:10.1038/ajg.2012.131

15. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101(4):927-934. doi:10.1016/0016-5085(91)90717-y

16. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000;46(1):78-82. doi:10.1136/gut.46.1.78

17. Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional Disorders: Children and Adolescents. Gastroenterology. 2016;150(6):1456-1468. doi:10.1053/j.gastro.2016.02.015

18. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804-811. doi:10.1136/gut.47.6.804

19. Folks DG. The interface of psychiatry and irritable bowel syndrome. Curr Psychiatry Rep. 2004;6(3):210-215. doi:10.1007/s11920-004-0064-8

20. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med. 1990;113(11):828-833. doi:10.7326/0003-4819-113-11-828

21. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010;25(2):252-258. doi:10.1111/j.1440-1746.2009.06149.x

22. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799-804. doi:10.1053/gast.2001.27995

23. Pimentel M, Lembo A. Microbiome and its role in irritable bowel syndrome. Dig Dis Sci. 2020;65(3):829-839. doi:10.1007/s10620-020-06109-5

24. Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11(1 Suppl):S17-S26.

25. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut. 1973;14(2):125-132. doi:10.1136/gut.14.2.125

26. Mayer EA, Naliboff BD, Craig AD. Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology. 2006;131(6):1925-1942. doi:10.1053/j.gastro.2006.10.026

27. Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983;24(5):405-411. doi:10.1136/gut.24.5.405

28. Bassotti G, Germani U, Morelli A. Human colonic motility: physiological aspects. Int J Colorectal Dis. 1995;10(3):173-180. doi:10.1007/BF00298538

29. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397-414. doi:10.1053/j.gastro.2006.11.002

30. Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci. 2018;12:49. doi:10.3389/fnins.2018.00049

31. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159-176. doi:10.1136/gutjnl-2012-302167

32. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412-419. doi:10.1111/j.1572-0241.2003.07234.x

33. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693-702. doi:10.1053/j.gastro.2003.11.055

34. Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil. 2007;19(7):545-552. doi:10.1111/j.1365-2982.2007.00925.x

35. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30(7):707-717. doi:10.1111/j.1365-2036.2009.04081.x

36. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2):320-328. doi:10.1053/j.gastro.2013.04.051

37. Drossman DA, Hasler WL. Rome IV—Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-1261. doi:10.1053/j.gastro.2016.03.035

38. Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7(1):68-72. doi:10.1016/j.cgh.2008.07.008

39. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122(4):1140-1156. doi:10.1053/gast.2002.32392

40. Williams RE, Hartmann KE, Sandler RS, Miller WC, Steege JF. Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain. Am J Obstet Gynecol. 2005;192(3):761-767. doi:10.1016/j.ajog.2004.10.600

41. Aurora SK, Kori SH, Barrodale P, McDonald SA, Haseley D. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46(1):57-63. doi:10.1111/j.1526-4610.2006.00311.x

42. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920-924. doi:10.3109/00365529709011203

43. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22. doi:10.1053/gast.2000.8523

44. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet. 2001;358(9292):1504-1508. doi:10.1016/S0140-6736(01)06581-3

45. Pardi DS, Kelly CP. Microscopic colitis. Gastroenterology. 2011;140(4):1155-1165. doi:10.1053/j.gastro.2011.02.003

46. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705-2712. doi:10.1001/jama.291.22.2705

47. National Institute for Health and Care Excellence. Irritable bowel syndrome in adults: diagnosis and management (CG61). 2008, updated 2017. https://www.nice.org.uk/guidance/cg61

48. Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. doi:10.1136/gutjnl-2021-324598

49. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915-922. doi:10.1038/ajg.2010.480

50. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. doi:10.1136/bmj.a2313

51. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75. doi:10.1053/j.gastro.2013.09.046

52. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-1561. doi:10.1038/ajg.2014.202

53. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355-361. doi:10.1046/j.1365-2036.2001.00937.x

54. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39(6):530-536. doi:10.1016/j.dld.2007.02.006

55. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58(3):367-378. doi:10.1136/gut.2008.163162

56. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55(8):1095-1103. doi:10.1136/gut.2005.077503

57. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77-80. doi:10.3109/00365528709091002

58. Pimentel M, Lembo A, Chey WD, et al; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22-32. doi:10.1056/NEJMoa1004409

59. Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63(10):1617-1625. doi:10.1136/gutjnl-2013-305989

60. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508-1515. doi:10.1038/ajg.2013.197

61. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714-1724. doi:10.1038/ajg.2012.255

62. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-341. doi:10.1111/j.1365-2036.2008.03881.x

63. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357-365. doi:10.1136/gut.2008.162404

64. Lackner JM, Jaccard J, Krasner SS, Katz LA, Gudleski GD, Holroyd K. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol. 2008;6(8):899-906. doi:10.1016/j.cgh.2008.03.004

65. Whorwell PJ, Prior A, Faragher EB. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet. 1984;2(8414):1232-1234. doi:10.1016/s0140-6736(84)92793-4

66. Gaylord SA, Palsson OS, Garland EL, et al. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol. 2011;106(9):1678-1688. doi:10.1038/ajg.2011.184

67. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004;126(7):1665-1673. doi:10.1053/j.gastro.2004.02.020

68. Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.